Lv31
314 积分 2025-05-13 加入
Efficacy and safety of lorlatinib in first-line and later-line treatment for Chinese patients: a real-world study with retrospective and prospective bidirectional cohorts
3小时前
求助中
ALK重排非小细胞肺癌脑转移患者不同治疗模式疗效对比及预后因素分析
4小时前
待确认
P1.12B.05 Patient and Oncologist Preferences for ALK+ Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments
1个月前
已关闭
非小细胞肺癌脑转移研究进展
1个月前
已完结
SA59 Evaluating the Optimal TKI for Patients With ALK Positive Advanced Non-Small-Cell Lung Cancer (aNSCLC) in the First Line (1L) Setting: An Updated Systematic Literature Review (SLR) and Network Meta-Analysis (NMA)
1个月前
已关闭
常规免疫组织化学初筛ALK阳性非小细胞肺癌专家共识
1个月前
已完结
Modeling Challenges for Cancer Drugs With Unprecedented Outcomes: Lorlatinib in the First Line Setting of ALK+ aNSCLS As a Case Study
1个月前
已关闭
Management of EGFR-Variant and ALK-Positive Non–Small Cell Lung Cancer Brain Metastasis
1个月前
已完结
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
1个月前
已完结
Depth of response and progression-free survival in patients with advanced ALK-positive non–small-cell lung cancer treated with lorlatinib
1个月前
已完结
皖公网安备34019202002308
